Long Shortz with Prescient Therapeutics: First US trial site launches for PTX-100

Prescient Therapeutics announces the initiation of its first US site for the Phase 2a trial of PTX-100.

Stockhead’s Tylah Tully catches up with Prescient Therapeutics (ASX:PTX) CEO James McDonnell after the company hit a major milestone with the initiation of its first US site for the Phase 2a trial of PTX-100.

McDonnell also discusses the progress of Australian trial locations and, with enrolment underway, explains how the company is now focused on reaching a 20-patient milestone to evaluate early results.

This video was developed in collaboration with Prescient Therapeutics, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.

Originally published as Long Shortz with Prescient Therapeutics: First US trial site launches for PTX-100